NUMBERS NEEDED TO TREAT AND COSTS PER IMPROVED OUTCOME AMONG TREATMENTS FOR MYASTHENIA GRAVIS

被引：0
|
作者：
Qi, C. [1 ]
Wang, J. [2 ]
Yang, H. [2 ]
Gelinas, D. [1 ]
Brauer, E. [1 ]
Du, M. [2 ]
Sun, R. [2 ]
Phillips, G. [1 ]
机构：
[1] Argenx Inc, Boston, MA USA
[2] Anal Grp Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE121
引用
收藏
页码：S358 / S358
页数：1
相关论文
共 24 条
  • [11] Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan
    Ueno, Fumiaki
    Doi, Michio
    Kawai, Yumi
    Ukawa, Naoto
    Cammarota, Jordan
    Betts, Keith A.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 80 - 85
  • [12] Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data
    Pisc, Julia
    Ting, Angela
    Skornicki, Michelle
    Sinno, Omar
    Lee, Edward
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2024, 13 (01)
  • [13] Numbers-needed-to-treat and associated costs of care for treatment of moderate-to-severe psoriasis
    Hankin, C
    Feldman, SR
    Szczotka, A
    Fish, L
    VALUE IN HEALTH, 2005, 8 (03) : 330 - 330
  • [14] NUMBER NEEDED TO TREAT AND INCREMENTAL COSTS PER RESPONDER FOR BIOLOGICS IN ADULT PATIENTS WITH ACTIVE RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN THE RUSSIAN FEDERATION
    Mladov, V
    Sokolova, V
    Tolkacheva, D.
    VALUE IN HEALTH, 2021, 24 : S17 - S17
  • [15] EFFICACY OF TARGETED DRUGS FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN THE RUSSIAN FEDERATION: NUMBER NEEDED TO TREAT AND COSTS PER RESPONDER
    Sableva, N.
    Sokolova, V
    Tolkacheva, O.
    VALUE IN HEALTH, 2022, 25 (12) : S185 - S185
  • [16] NUMBER NEEDED TO TREAT AND INCREMENTAL COSTS PER RESPONDER FOR BIOLOGICS AND TARGETED SYNTHETIC DRUGS IN ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION
    Mladov, V
    Sokolova, V
    Tolkacheva, D.
    VALUE IN HEALTH, 2022, 25 (01) : S189 - S189
  • [17] Long-Term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-Based Study
    Cai, Qian
    Batista, Alberto E.
    Borsum, Jakob
    Zhang, Qiaoyi
    Isheden, Gabriel
    Kunovszki, Peter
    Gandhi, Kavita
    Heerlein, Kristin
    Brauner, Susanna
    NEUROEPIDEMIOLOGY, 2024, 58 (06) : 460 - 469
  • [18] UTILIZING REAL-WORLD EVIDENCE TO ESTIMATE TREATMENT COSTS AMONG NORWEGIAN PATIENTS WITH MYASTHENIA GRAVIS TREATED WITH INTRAVENOUS IMMUNOGLOBULIN (IVIG)
    Bugge, C.
    Engebretsen, I
    Kristiansen, I. S.
    Arneberg, F.
    Gilhus, N. E.
    VALUE IN HEALTH, 2023, 26 (12) : S58 - S58
  • [19] Life-years, QALYs, costs and numbers needed to treat associated with exenatide once weekly versus insulin and pioglitazone treatment for type 2 diabetes: an Archimedes model simulation
    Alperin, P.
    Gaebler, J. A.
    Soto-Campos, G.
    Hoogwerf, B.
    Wintle, M.
    Maggs, D.
    Blickensderfer, A.
    Bruhn, D.
    Peskin, B.
    DIABETOLOGIA, 2011, 54 : S327 - S327
  • [20] Trends in Outcomes and Hospitalization Costs among Pediatric Myasthenia Gravis Patients in the United States. Data from Kids' Inpatient Database (KID) 1997-2009
    Sander, Howard
    Elenein, Rania
    He, Wenzhuan
    Sheikh, Zubeda
    Al Qudah, Zaid
    Souayah, Nizar
    NEUROLOGY, 2013, 80
123